Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks Investment Research • 10/09/26
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)Newsfile Corp • 10/08/26
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares FlyInvestors Business Daily • 10/08/26
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPRNewsWire • 10/08/26
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive YearPRNewsWire • 09/29/26
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga • 09/23/26
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea SyndromePRNewsWire • 09/16/26
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story AliveSeeking Alpha • 09/09/26
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales JumpZacks Investment Research • 08/06/26
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26